Treats bronchoconstriction. ANDA 216426, held by LEXENPHARM. Formoterol Fumarate.
As of Nov 21, 2026, ANDA 216426 (Formoterol Fumarate), held by LEXENPHARM, was first approved by FDA on Oct 22, 2024, with 0 approved supplements and 0 published complete response letters.
Formoterol fumarate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Important limitations of use: Formoterol fumarate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ( 1.2, 5.2 ) Formoterol fumarate inhalation solution is not indicated to treat asthma. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 22, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Formoterol Fumarate0.02MG/2ML · solution;inhalation | Formoterol Fumarate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters